Stockreport

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

Reneo Pharmaceuticals, Inc. - Class A  (RPHM) 
PDF -- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Ka), initially in breast cancer -- On tr [Read more]